FTC Continues to Rage Against Device Patent Listings in the Orange Book
The FDA Law Blog
MARCH 26, 2024
Koblitz — The FTC appears to be on a mission to cleanse the Orange Book of patents it deems improperly listed. For the second time in recent years, the FTC has filed an Amicus Brief explaining exactly which patents should not be in the Orange Book. Because a “drug product” is defined by regulation as a “Finished dosage form.
Let's personalize your content